Moreover, we discovered that plasma versican levels were significantly greater in the mutation group(e.g., EGFR, ALK) of NSCLC than in the non-mutation group (t = 2.486; P = 0.014; Fig. 5C). This evidence concerns the gene VCAN and non-small cell lung carcinoma.